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Introduction
Oestrogen may maintain the growth of some breast cancers,
and oestrogen deprivation therapy can cause tumour regres-
sion. However, even in breast cancers that possess
oestrogen receptors (the key transcription factor in oestrogen
signalling), response rates to endocrine therapy are only 50%
to 60%, hence the interest in identifying additional factors
that might predict response/resistance to hormone therapy.
In this respect, it had been hoped that molecules that are
regulated by oestrogen would be excellent candidates.
However, this review makes the case that oestrogen-
regulated markers are unlikely to be robust indicators of
hormone dependence in breast cancers.
Evidence is based on correlating oestrogen regulated markers
(identified on account of having an oestrogen response
element [ERE] in the promoter region of their genes and
being classically oestrogen regulated in many hormone-
sensitive tissues [the example used is the progesterone
receptor (PR)], expression being regulated by oestrogen in
breast cancer cell lines, and expression being regulated by
oestrogen deprivation therapy in primary breast cancers) with
clinical response to endocrine therapy either in patients with
advanced breast cancer or in the neoadjuvant setting.
Progesterone receptor and clinical response
to neoadjuvant hormone therapy
Two major randomized trials of neoadjuvant endocrine therapy
(P024 and IMPACT [Immediate Preoperative Arimidex
Compared to Tamoxifen]) and one other large study assessed
the relationship of PR status to clinical response to either
tamoxifen or an aromatase inhibitor. All found a higher
incidence of PR positivity in clinically responding tumours
[1-3] as compared with nonresponders. However, it is clear
that a substantial number of PR-negative tumours respond to
endocrine therapy, and conversely that many clinical
nonresponding tumours possess PR. Consequently, PR is a
poor marker of clinical response to endocrine therapy.
It could be argued that rather than measure pretreatment PR
expression, it might be more informative to relate change in
PR level with clinical response. Treatment with aromatase
inhibitors is associated with a reduction in immuno-
histochemical staining for PR [1-3]. However, this occurs in
about 90% of cases irrespective of clinical response. It is
clear that downregulation of PR occurs in most clinically
nonresponsive tumours.
Genes regulated by oestrogen in breast
cancer cell lines
Many studies have been conducted to determine the effects
of oestrogen addition/withdrawal in breast cancer cell lines
maintained in culture or as xenografts in immunosuppressed
animals; most have used the MCF7 cell line. Five studies
published since 2000 [4-8] have been used as a database in
which to identify oestrogen-regulated genes. No single gene
was listed in all five publications, but two were quoted in four
publications and nine in at least three journals. A total of 141
genes were confirmed by publication in two journals. The
general lack of consensus probably reflects variables such as
the amount of oestrogen used, duration of exposure, different
sources of cell lines, conditions of growth and different
platforms of assays. These 141 genes were compared with
the gene signatures based on a pretreatment tumour analysis
from patients with advanced breast cancer and predicting
response to tamoxifen, as defined by Janssen and coworkers
[9]. The overlap between the genes was minimal. However,
such a comparison is based upon change in expression for
the cell line gene set and pretreatment expression for the
clinical response signature.
To avoid this confounder, the 141 gene list has been
compared with genes that most significantly changed on
letrozole neoadjuvant treatment but differentially expressed
between responders and nonresponders [10]. No correlation
was found between the two sets of genes. Although the
identity of these genes remains unreported, none were found
among the 141 regulated by oestrogen in the MCF7 cell line.
There are two major reasons for this. First, some genes
change in both nonresponding and responding cases.
Second, some genes change in culture following oestrogen
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© 2007 BioMed Central Ltdexposure/withdrawal but are relatively unaffected by letrozole
treatment in primary tumours. This can be illustrated, as is
shown in Figure 1, by comparing the change in expression of
the nine most commonly quoted oestrogen-regulated genes
in MCF7 in responding and nonresponding tumours. It can be
seen that genes such as NRIP1, STC2, CCND1, MYB and
TFF1 are frequently downregulated by letrozole treatment in
clinically responding tumours, but this also occurs in many of
the nonresponding cases. Other genes such as AURKA,
IGFBP4, SLC7A5 and TPD52-1 are relatively unaffected by
treatment in both responders and nonresponders.
Genes that are influenced by endocrine
therapy in breast cancer
A list of genes most significantly influenced by neoadjuvant
treatment (at 14 days) with letrozole has been published [10].
However, this has no overlap with genes whose expression is
differentially changed between clinical responders and
nonresponders at the same time point (unpublished data). The
reason for this is that expression levels of oestrogen-regulated
genes are changed by therapy per se and are not restricted to
clinically responding tumours, and also change in clinically
resistant cases. Accurate prediction of clinical response
requires a novel gene discovery programme to identify markers
that are regulated by oestrogen in clinically responding tumours
alone (or conversely in clinically resistant tumours alone).
It is concluded that oestrogen-regulated genes are molecular
markers of oestrogen sensitivity (not dependence); that
expression profiles and molecular responses to endocrine
therapy in clinically resistant tumours may be similar to clinical
responders; and, therefore, that most oestrogen-regulated
genes are unlikely to be robust markers of clinical response
to endocrine therapy.
Acknowledgement
This article has been published as part of Breast Cancer Research
Volume 9 Supplement 2, 2007: Controversies in Breast Cancer. The
full contents of the supplement are available online at http://breast-
cancer-research.com/supplements/9/S2.
References
1. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke
F, Miller WR, Evans DB, Dugan M, Brady C, et al.: Letrozole is
more effective neoadjuvant endocrine therapy than tamoxifen
for ErbB-1- and/or ErbB-2-positive, estrogen receptor-posi-
tive primary breast cancer: evidence from a phase III random-
ized trial. J Clin Oncol 2001, 19:3808-3816.
2. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boedding-
haus I, Salter J, Detre S, Hills M, Ashley S, et al.:  Biomarker
changes during neoadjuvant anastrozole, tamoxifen, or the
combination: influence of hormonal status and HER-2 in
breast cancer: a study from the IMPACT trialists. J Clin Oncol
2005, 23:2477-2492.
3. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ:
Proliferation, steroid receptors and clinical/pathological
response in breast cancer treated with letrozole. Br J Cancer
2006, 94:1051-1056.
4. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ,
Gaddis S, MacLeod MC, Aldaz CM: Effects of estrogen on
global gene expression: identification of novel targets of
estrogen action. Cancer Res 2000, 60:5977-5983.
5. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbo-
gen BS: Profiling of estrogen up- and down-regulated gene
expression in human breast cancer cells: insights into gene net-
works and pathways underlying estrogenic control of prolifera-
tion and cell phenotype. Endocrinology 2003, 144:4562-4574.
6. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R,
Hayashi S: Development of cDNA microarray for expression
profiling of estrogen-responsive genes. J Mol Endocrinol
2002, 29:175-192.
7. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA,
Perou CM: Estrogen-regulated genes predict survival in
hormone receptor-positive breast cancers. J Clin Oncol 2006,
24:1656-1664.
8. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD,
Chinnaiyan AM, Lippman ME, Rae JM: Genes regulated by estro-
gen in breast tumor cells in vitro are similarly regulated in vivo
in tumor xenografts and human breast tumors. Genome Biol
2006, 7:R28.
9. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Rit-
stier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen
H, Dorssers LC, et al.: Molecular classification of tamoxifen-
resistant breast carcinomas by gene expression profiling. J
Clin Oncol 2005, 23:732-740.
10. Miller WR, Larionov A, Renshaw L, Anderson TJ, White S,
Hampton G, Walker JR, Ho S, Krause A, Evans DB, et al.: Aro-
matase inhibitors: gene discovery. J Steroid Biochem Mol Biol
2007, 106:130-142.
Breast Cancer Research    Vol 9 Suppl 2 Miller
Page 2 of 2
(page number not for citation purposes)
Figure 1
Changes in tumour expression of oestrogen-regulated genes after 14 days’ neoadjuvant treatment with letrozole.